UPDATE: Phase 3 Pivotal Trial for 177Lu-NYM032

A PSMA-targeted radioligand built on a compound called NYM032 is heading into the pivotal phase 3 trial that will decide whether its early data hold up. The molecule can be labeled with gallium-68 for PET imaging or lutetium-177 for therapy, giving a matched diagnose-and-treat pair. In mouse tumor models, escalating the dose from 18.5 to […]

Beyond CRISPR? TIGRa: The Tiny Genetic Switch That Could Let the Body Heal Itself

Scientists at Stanford Medicine have built a new tool called TIGRa that can switch on helpful genes directly inside living cells. In a mouse study, it helped protect the eyes from a type of damage seen in glaucoma, and the discovery was published in the journal Cell Stem Cell. It could eventually lead to treatments […]